Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients.
Future Oncol
; 17(7): 807-815, 2021 Mar.
Article
en En
| MEDLINE
| ID: mdl-33508980
ABSTRACT
Background:
Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients &methods:
We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223.Results:
Median overall survival (OS) from the start of first-line treatment was 39.8 months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5 months; p < 0.0001).Conclusions:
Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Óseas
/
Radio (Elemento)
/
Radiofármacos
/
Antagonistas de Receptores Androgénicos
/
Neoplasias de la Próstata Resistentes a la Castración
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Future Oncol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Italia